Overview

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is an prospective, multicenter, single-arm clinical study.
Phase:
Phase 4
Details
Lead Sponsor:
Hebei Medical University Fourth Hospital
Treatments:
Bevacizumab